3 Coronavirus Vaccine Stocks That Still Have Strong Upside

As the market swoons over the latest coronavirus vaccine updates from Pfizer and Moderna, it's easy to lose sight of the fact that there are still other candidates in the works. GlaxoSmithKline (NYSE: GSK), Novavax (NASDAQ: NVAX), and Johnson & Johnson (NYSE: JNJ) aren't about to start selling their vaccines tomorrow, but they'll probably report on their clinical trial data before the end of the year. In its coronavirus vaccine effort, GlaxoSmithKline is collaborating with Sanofi (NASDAQ: SNY), one of its major competitors.